Overview Dividends

(CLBT) Cellebrite DI - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011794802

Forensics Software, Extraction Tools, Analysis Platform, Case Management

CLBT EPS (Earnings per Share)

EPS (Earnings per Share) of CLBT over the last years for every Quarter: "2020-09": 0, "2020-12": -0.2013, "2021-03": 0.22, "2021-06": 0.05, "2021-09": 0.08, "2021-12": 0.03, "2022-03": 0.01, "2022-06": 0.17, "2022-09": 0.01, "2022-12": 0.08, "2023-03": 0.03, "2023-06": 0.05, "2023-09": 0.09, "2023-12": 0.12, "2024-03": 0.08, "2024-06": 0.1, "2024-09": 0.14, "2024-12": 0.1, "2025-03": 0.1, "2025-06": 0.12, "2025-09": 0,
EPS Growth (3Y CAGR): -55.76%
EPS Trend (3Y Correlation): 12.8%

CLBT Revenue

Revenue of CLBT over the last years for every Quarter: 2020-09: 53.241, 2020-12: 57.168, 2021-03: 53.283, 2021-06: 59.168, 2021-09: 65.887, 2021-12: 67.908, 2022-03: 62.385, 2022-06: 62.573, 2022-09: 71.675, 2022-12: 74.018, 2023-03: 71.234, 2023-06: 76.684, 2023-09: 84.179, 2023-12: 93.013, 2024-03: 89.582, 2024-06: 95.714, 2024-09: 106.858, 2024-12: 109.049, 2025-03: 107.549, 2025-06: 113.276, 2025-09: null,
Revenue Growth (3Y CAGR): 18.11%
Revenue Trend (3Y Correlation): 97.3%
Risk via 10d forecast
Volatility 41.5%
Value at Risk 5%th 60.8%
Reward
Sharpe Ratio -0.33
Alpha -38.62
Character
Hurst Exponent 0.505
Beta 1.295
Drawdowns 3y
Max DD 48.00%
Mean DD 12.28%

Description: CLBT Cellebrite DI November 08, 2025

Cellebrite DI Ltd. (NASDAQ: CLBT) supplies a comprehensive digital-forensics suite that enables legally sanctioned investigations across all continents. Its flagship products-Inseyets, Pathfinder, Smart Search, and Guardian-cover the full evidence lifecycle from acquisition and decoding to automated analysis, visualization, and case management, serving law-enforcement, border-control, and corporate security agencies tackling crimes such as child exploitation, terrorism, human trafficking, and cryptocurrency fraud.

In FY 2023 the company reported revenue of $215 million, up roughly 23 % year-over-year, with subscription-based recurring revenue now representing about 70 % of total sales and a gross margin near 78 %. Growth is being driven by expanding government budgets for cyber-crime response and the broader digital-forensics market, which is projected to compound at ~11 % annually through 2028. Cellebrite’s recent rollout of Endpoint Inspector and Endpoint Mobile Now extends its addressable enterprise base, adding a recurring-revenue stream beyond traditional law-enforcement contracts.

For a deeper quantitative assessment, you may find ValueRay’s analyst notes on CLBT useful.

CLBT Stock Overview

Market Cap in USD 3,765m
Sub-Industry Application Software
IPO / Inception 2021-08-31
Return 12m vs S&P 500 -26.23%
Analyst Rating 4.75 of 5

CLBT Dividends

Currently no dividends paid

CLBT Growth Ratios

CAGR 48.18%
CAGR/Max DD Calmar Ratio 1.00
CAGR/Mean DD Pain Ratio 3.92
Current Volume 1135.2k
Average Volume 1095.9k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-150.9m TTM) > 0 and > 6% of Revenue (6% = 26.2m TTM)
FCFTA 0.19 (>2.0%) and ΔFCFTA 3.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 67.81% (prev 47.45%; Δ 20.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.20 (>3.0%) and CFO 161.1m > Net Income -150.9m (YES >=105%, WARN >=100%)
Net Debt (-156.9m) to EBITDA (72.4m) ratio: -2.17 <= 3.0 (WARN <= 3.5)
Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (249.0m) change vs 12m ago 25.15% (target <= -2.0% for YES)
Gross Margin 84.38% (prev 84.19%; Δ 0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 64.99% (prev 65.13%; Δ -0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.27 (EBITDA TTM 72.4m / Interest Expense TTM 225.3m) >= 6 (WARN >= 3)

Altman Z'' 2.21

(A) 0.38 = (Total Current Assets 606.1m - Total Current Liabilities 310.0m) / Total Assets 787.4m
(B) -0.16 = Retained Earnings (Balance) -128.0m / Total Assets 787.4m
(C) 0.09 = EBIT TTM 61.9m / Avg Total Assets 672.0m
(D) -0.33 = Book Value of Equity -125.3m / Total Liabilities 379.0m
Total Rating: 2.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.84

1. Piotroski 4.50pt = -0.50
2. FCF Yield 4.49% = 2.25
3. FCF Margin 34.12% = 7.50
4. Debt/Equity 0.05 = 2.50
5. Debt/Ebitda -2.17 = 2.50
6. ROIC - WACC (= 5.72)% = 7.15
7. RoE -42.94% = -2.50
8. Rev. Trend 97.32% = 7.30
9. EPS Trend 12.82% = 0.64

What is the price of CLBT shares?

As of November 11, 2025, the stock is trading at USD 15.61 with a total of 1,135,172 shares traded.
Over the past week, the price has changed by -6.08%, over one month by -18.27%, over three months by +15.46% and over the past year by -15.02%.

Is Cellebrite DI a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Cellebrite DI (NASDAQ:CLBT) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 76.84 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLBT is around 16.34 USD . This means that CLBT is currently overvalued and has a potential downside of 4.68%.

Is CLBT a buy, sell or hold?

Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CLBT price?

Issuer Target Up/Down from current
Wallstreet Target Price 23.6 51%
Analysts Target Price 23.6 51%
ValueRay Target Price 18.6 19.1%

CLBT Fundamental Data Overview November 11, 2025

Market Cap USD = 3.76b (3.76b USD * 1.0 USD.USD)
P/E Forward = 37.1747
P/S = 8.6204
P/B = 11.2324
Beta = 1.284
Revenue TTM = 436.7m USD
EBIT TTM = 61.9m USD
EBITDA TTM = 72.4m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.47m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -156.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.31b USD (3.76b + Debt 22.3m - CCE 472.2m)
Interest Coverage Ratio = 0.27 (Ebit TTM 61.9m / Interest Expense TTM 225.3m)
FCF Yield = 4.49% (FCF TTM 149.0m / Enterprise Value 3.31b)
FCF Margin = 34.12% (FCF TTM 149.0m / Revenue TTM 436.7m)
Net Margin = -34.56% (Net Income TTM -150.9m / Revenue TTM 436.7m)
Gross Margin = 84.38% ((Revenue TTM 436.7m - Cost of Revenue TTM 68.2m) / Revenue TTM)
Gross Margin QoQ = 84.39% (prev 83.74%)
Tobins Q-Ratio = 4.21 (Enterprise Value 3.31b / Total Assets 787.4m)
Interest Expense / Debt = 6.04% (Interest Expense 1.35m / Debt 22.3m)
Taxrate = 6.32% (1.31m / 20.8m)
NOPAT = 57.9m (EBIT 61.9m * (1 - 6.32%))
Current Ratio = 1.96 (Total Current Assets 606.1m / Total Current Liabilities 310.0m)
Debt / Equity = 0.05 (Debt 22.3m / totalStockholderEquity, last quarter 408.4m)
Debt / EBITDA = -2.17 (Net Debt -156.9m / EBITDA 72.4m)
Debt / FCF = -1.05 (Net Debt -156.9m / FCF TTM 149.0m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.17% (Net Income -150.9m / Total Assets 787.4m)
RoE = -42.94% (Net Income TTM -150.9m / Total Stockholder Equity 351.6m)
RoCE = 16.54% (EBIT 61.9m / Capital Employed (Equity 351.6m + L.T.Debt 22.3m))
RoIC = 16.48% (NOPAT 57.9m / Invested Capital 351.6m)
WACC = 10.76% (E(3.76b)/V(3.79b) * Re(10.79%) + D(22.3m)/V(3.79b) * Rd(6.04%) * (1-Tc(0.06)))
Discount Rate = 10.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.16%
[DCF Debug] Terminal Value 73.04% ; FCFE base≈124.2m ; Y1≈153.2m ; Y5≈261.5m
Fair Price DCF = 11.60 (DCF Value 2.84b / Shares Outstanding 244.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 12.82 | EPS CAGR: -55.76% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.32 | Revenue CAGR: 18.11% | SUE: 0.39 | # QB: 0

Additional Sources for CLBT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle